D-1701-2019 Class II Terminated
FDA drug recall D-1701-2019 was initiated by RXQ Compounding LLC on Jun 19, 2019 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Sep 16, 2022).
Recall details
- Product Type
- Drugs
- Report Date
- Aug 14, 2019
- Initiation Date
- Jun 19, 2019
- Termination Date
- Sep 16, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
RIBOFLAVIN 0.1% OPHTHALMIC SOLUTION SYRINGE, 2 ML per syringe. RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0923-02
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
Nationwide USA
Code information
All lots within expiry
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1701-2019
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for RXQ Compounding LLC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.